Latest Recruitment News

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Noxopharm has initiated its HERACLES clinical trial for SOF-SKN, marking a key milestone for its Sofra platform, while deepening partnerships and actively seeking new funding to sustain development.

IGO Limited reported robust operational performance in Q4 FY25 with improved safety and higher production at Greenbushes and Nova, while facing significant impairment at its Kwinana lithium refinery.

EMVision Medical Devices reports strong progress in its pivotal trial for the emu™ bedside brain scanner and successful aeromedical testing of its First Responder device, backed by a $5 million government grant and $10.5 million in cash reserves.

OncoSil Medical has reported a record 20% quarterly increase in dose sales and secured $8.7 million in new capital, underpinning its clinical and commercial expansion in pancreatic cancer treatment.

Merino & Co reported a robust quarter highlighted by the successful launch of its Merino possum range, strategic international hires, and a solid cash position of $3.02 million, positioning the company for sustained expansion.

Chimeric Therapeutics has advanced its CHM CDH17 CAR-T program with dose escalation and FDA Fast Track status, alongside promising early results in AML trials and a successful $6.6 million capital raise.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

OpenLearning Limited reported a robust Q2 FY25 with 22% year-on-year SaaS ARR growth to $2.65 million, driven by significant multi-year contract wins and expanding global customer base. The company’s AI-powered LMS strategy is delivering larger deals and improved cash flow metrics.

Avecho Biotechnology reports strong progress in its Phase III clinical trial for a CBD-based insomnia treatment, with recruitment accelerating across multiple Australian sites and interim results expected early next year.

EDU Holdings has reported record first-half FY25 results, propelled by strong enrolment growth at its Ikon Institute, while its vocational arm ALG faces headwinds from tighter student visa policies.

EMVision Medical Devices has secured ethics approvals for two pivotal clinical studies and received a $400,000 milestone payment, marking significant progress toward commercialising its portable First Responder brain scanner.